nifurtimox and Seizures

Human African trypanosomiasis (HAT; sleeping sickness) caused by Trypanosoma brucei gambiense is a fatal disease. Current treatment options for patients with second-stage disease are toxic, ineffective, or impractical. We assessed the efficacy and safety of nifurtimox-eflornithine combination therapy (NECT) for second-stage disease compared with the standard eflornithine regimen.. A multicentre, randomised, open-label, active control, phase III, non-inferiority trial was done at four HAT treatment centres in the Republic of the Congo and the Democratic Republic of the Congo. Patients aged 15 years or older with confirmed second-stage T b gambiense infection were randomly assigned by computer-generated randomisation sequence to receive intravenous eflornithine (400 mg/kg per day, every 6 h; n=144) for 14 days or intravenous eflornithine (400 mg/kg per day, every 12 h) for 7 days with oral nifurtimox (15 mg/kg per day, every 8 h) for 10 days (NECT; n=143). The primary endpoint was cure (defined as absence of trypanosomes in body fluids and a leucocyte count

Topics: Administration, Oral; Adult; Animals; Congo; Democratic Republic of the Congo; Drug Administration Schedule; Drug Therapy, Combination; Eflornithine; Female; Fever; Follow-Up Studies; Humans; Infections; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Nifurtimox; Safety; Seizures; Treatment Outcome; Trypanocidal Agents; Trypanosoma brucei gambiense; Trypanosomiasis, African